Citations (67)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Qiang Yin, Peng Li, Peng Wang, Zhen Zhang, Qun Liu, Zengfeng Sun, Wenliang Li, Li Ma & Xiaoguang Wang. (2021) Alectinib Together with Intracranial Therapies Improved Survival Outcomes in Untreated ALK-Positive Patients with Non-Small-Cell Lung Cancer and Symptomatic and Synchronic Brain Metastases: A Retrospective Study. OncoTargets and Therapy 14, pages 5533-5542.
Read now
Read now
Amanda M. Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan, Elizabeth H. Marchlewicz, Christina Chebili-Larson, Stella Min & Deepa S. Subramaniam. (2021) Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US . Journal of Medical Economics 24:1, pages 328-338.
Read now
Read now
Huamao M. Lin, Xiaoyun Pan, Peijie Hou, Hui Huang, Yanyu Wu, Kaili Ren & Mohammad Jahanzeb. (2020) Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors. Journal of Medical Economics 23:8, pages 894-901.
Read now
Read now
Karen Reckamp, Huamao M. Lin, Joice Huang, Irina Proskorovsky, William Reichmann, Stanimira Krotneva, David Kerstein, Hui Huang & Joseph Lee. (2019) Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Current Medical Research and Opinion 35:4, pages 569-576.
Read now
Read now
Marco D DiBonaventura, William Wong, Bijal Shah-Manek & Mathias Schulz. (2018) Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA. OncoTargets and Therapy 11, pages 75-82.
Read now
Read now
Ancilla W. Fernandes, Bingcao Wu & Ralph M. Turner. (2017) Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. Journal of Medical Economics 20:11, pages 1136-1147.
Read now
Read now
Alessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, Giuseppa Ferraro, Antonino Scimone, Giuseppe Bronte, Antonio Russo, Christian Rolfo & Vincenzo Adamo. (2016) Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Review of Anticancer Therapy 16:6, pages 615-623.
Read now
Read now
A. Guérin, M. Sasane, K. Dea, J. Zhang, K. Culver, R. Nitulescu, E. Q. Wu & A. R. Macalalad. (2016) The economic burden of brain metastasis among lung cancer patients in the United States. Journal of Medical Economics 19:5, pages 526-536.
Read now
Read now
Articles from other publishers (59)
Geoffrey Liu & Vincent K. Lam. (2023) Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis. Advances in Therapy.
Crossref
Crossref
Tamta Makharadze, Ruben G. W. Quek, Tamar Melkadze, Miranda Gogishvili, Cristina Ivanescu, Davit Giorgadze, Mikhail Dvorkin, Konstantin Penkov, Konstantin Laktionov, Gia Nemsadze, Marina Nechaeva, Irina Rozhkova, Ewa Kalinka, Christian Gessner, Brizio Moreno‐Jaime, Rodolfo Passalacqua, Gerasimos Konidaris, Petra Rietschel & Giuseppe Gullo. (2023) Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3. Cancer 129:14, pages 2256-2265.
Crossref
Crossref
Saadettin Kilickap, Sertac Ak, Oldac U Dursun, Mehmet AN Sendur, Nuri Karadurmus & Umut Demirci. (2023) Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events. Future Oncology.
Crossref
Crossref
Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On & Geoffrey Liu. (2023) Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience. Current Oncology 30:7, pages 6559-6574.
Crossref
Crossref
Benjamin J Solomon, Todd M Bauer, Tony S K Mok, Geoffrey Liu, Julien Mazieres, Filippo de Marinis, Yasushi Goto, Dong-Wan Kim, Yi-Long Wu, Jacek Jassem, Froylán López López, Ross A Soo, Alice T Shaw, Anna Polli, Rossella Messina, Laura Iadeluca, Francesca Toffalorio & Enriqueta Felip. (2023) Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. The Lancet Respiratory Medicine 11:4, pages 354-366.
Crossref
Crossref
Giulia Corrao, Matteo Franchi, Mattia Zaffaroni, Maria Giulia Vincini, Filippo de Marinis, Lorenzo Spaggiari, Roberto Orecchia, Giulia Marvaso & Barbara Alicja Jereczek-Fossa. (2023) Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy. Cancers 15:4, pages 1103.
Crossref
Crossref
Rolf Snijders, Linda Brom, Maurice Theunissen & Marieke van den Beuken-van Everdingen. (2023) Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers 15:3, pages 591.
Crossref
Crossref
Joanna K Tabor, Amanda Onoichenco, Vinayak Narayan, A Gabriella Wernicke, Randy S D’Amico & Morana Vojnic. (2023) Brain metastasis screening in the molecular age. Neuro-Oncology Advances 5:1.
Crossref
Crossref
Julien Mazieres, Laura Iadeluca, Alice T. Shaw, Benjamin J. Solomon, Todd M. Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Dong-Wan Kim, Tony Mok, Arlene Reisman, Holger Thurm, Anna M. Polli & Geoffrey Liu. (2022) Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer 174, pages 146-156.
Crossref
Crossref
Irfan Cicin, Claudio Martin, Carolina Kawamura Haddad, Sang-We Kim, Alexey Smolin, Arif Abdillah & Xue Yang. (2022) ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Critical Reviews in Oncology/Hematology 180, pages 103847.
Crossref
Crossref
Benjamin J. Solomon, Todd M. Bauer, Sai-Hong Ignatius Ou, Geoffrey Liu, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi-Long Wu, Oscar Arrieta, Jacek Jassem, Anna M. Calella, Gerson Peltz, Anna Polli, Holger Thurm & Tony Mok. (2022)
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With
ALK
-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
. Journal of Clinical Oncology 40:31, pages 3593-3602.
Crossref
Crossref
Yanyu Wu, Kaili Ren, Yin Wan & Huamao M Lin. (2022)
Economic burden in patients with anaplastic lymphoma kinase (
ALK
)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors
. Journal of Oncology Pharmacy Practice, pages 107815522211261.
Crossref
Crossref
Yoon-Bo Shim, Joo-Young Byun, Ju-Yong Lee, Eui-Kyung Lee & Mi-Hai Park. (2022) Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data. PLOS ONE 17:9, pages e0274876.
Crossref
Crossref
Holly CranmerIsabella KearnsMelanie YoungMichael J HumphriesDavid Trueman. (2022) The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective. Journal of Managed Care & Specialty Pharmacy 28:9, pages 970-979.
Crossref
Crossref
Yongluo Jiang, Yixing Wang, Sha Fu, Tao Chen, Yixin Zhou, Xuanye Zhang, Chen Chen, Li‐na He, Wei Du, Haifeng Li, Zuan Lin, Yuanyuan Zhao, Yunpeng Yang, Hongyun Zhao, Wenfeng Fang, Yan Huang, Shaodong Hong & Li Zhang. (2022)
A
CT
‐based radiomics model to predict subsequent brain metastasis in patients with
ALK
‐rearranged non–small cell lung cancer undergoing crizotinib treatment
. Thoracic Cancer 13:11, pages 1558-1569.
Crossref
Crossref
Alyssa Y. Li, Karolina Gaebe, Katarzyna J. Jerzak, Parneet K. Cheema, Arjun Sahgal & Sunit Das. (2022) Intracranial Metastatic Disease: Present Challenges, Future Opportunities. Frontiers in Oncology 12.
Crossref
Crossref
Mina Karimpour, Reyhaneh Ravanbakhsh, Melika Maydanchi, Ali Rajabi, Faezeh Azizi & Ali Saber. (2021) Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature. Biomedicine & Pharmacotherapy 143, pages 112190.
Crossref
Crossref
Wei Chen, Chunyu Li, Yafei Shi, Yujun Zhang, Dujia Jin, Mingyu Zhang, Mingming Bo & Guohui Li. (2021) A Comprehensive Analysis of Metabolomics and Transcriptomics Reveals Novel Biomarkers and Mechanistic Insights on Lorlatinib Crosses the Blood-Brain Barrier. Frontiers in Pharmacology 12.
Crossref
Crossref
Syed M Adil, Sarah E Hodges, Ryan M Edwards, Lefko T Charalambous, Zidanyue Yang, Musa Kiyani, Alexis Musick, Beth A Parente, Hui-Jie Lee, Katherine B Peters, Peter E Fecci & Shivanand P Lad. (2020) Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States. Neuro-Oncology Practice 7:6, pages 636-645.
Crossref
Crossref
Gracy Crane, Vlatka Smoljanovic, Nasreen Khan, Samuel Gally, Pascale Tomasini, Nuria Lara, Adam Gondos & Stefan Hammerschmidt. (2020) Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC. Lung Cancer 149, pages 144-153.
Crossref
Crossref
Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, Yu Yin, Yanyu Wu, Beth Nordstrom & Mark A. Socinski. (2020)
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for
ALK+
Non-Small Cell Lung Cancer
. The Oncologist 25:10, pages 867-877.
Crossref
Crossref
E. Simon & P. Tomasini. (2020) La prise en charge des métastases cérébrales du cancer bronchique. Revue des Maladies Respiratoires Actualités 12:2, pages 2S233-2S242.
Crossref
Crossref
Yingying Zhu, Ran Jia, Yang W. Shao, Liuqing Zhu, Qiuxiang Ou, Man Yu, Xue Wu & Yanbei Zhang. (2020) Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report. Frontiers in Oncology 10.
Crossref
Crossref
Georgios Tsakonas, Caroline Kamali, Luigi De Petris, Signe Friesland, Rolf Lewensohn & Simon Ekman. (2020) ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases. Cancers 12:7, pages 1804.
Crossref
Crossref
Yasushi Goto, Nobuyuki Yamamoto, Elizabeth T. Masters, Hironori Kikkawa, Jack Mardekian, Robin Wiltshire, Kanae Togo & Yuichiro Ohe. (2020) Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. Advances in Therapy 37:7, pages 3311-3323.
Crossref
Crossref
Manish Kumar, Kishore Kumar, Harinder Pal Singh, Suresh Nair, Amol Patel, Ashok Kumar & Sneha Soni. (2020) Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer. South Asian Journal of Cancer 9:02, pages 109-114.
Crossref
Crossref
Dolores Isla, Bartomeu Massuti, Martín Lázaro, Lucía Ruiz de Alda, Rocio Gordo, Nuria Ortega-Joaquín & Itziar Oyagüez. (2020) Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib. Lung Cancer Management 9:1.
Crossref
Crossref
Todd M. Bauer, Alice T. Shaw, Melissa L. Johnson, Alejandro Navarro, Justin F. Gainor, Holger Thurm, Yazdi K. Pithavala, Antonello Abbattista, Gerson Peltz & Enriqueta Felip. (2020) Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Targeted Oncology 15:1, pages 55-65.
Crossref
Crossref
Marine Sivignon, Rémi Monnier, Bertrand Tehard & Stéphane Roze. (2020) Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France. PLOS ONE 15:1, pages e0226196.
Crossref
Crossref
Albert Eusik Kim & Priscilla K. Brastianos. 2020. Central Nervous System Metastases. Central Nervous System Metastases
69
82
.
Jessica A. Wilcox & Lisa M. DeAngelis. 2020. Central Nervous System Metastases. Central Nervous System Metastases
3
18
.
Ali S. Haider, Raymond Sawaya & Sherise D. Ferguson. 2020. Central Nervous System Metastases. Central Nervous System Metastases
191
198
.
Jianjiao Ni, Guodong Li, Xi Yang, Li Chu, Jialei Wang, Yida Li, Liqing Zou, Yuan Li, Congying Xie & Zhengfei Zhu. (2019) Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses. Radiation Oncology 14:1.
Crossref
Crossref
Maurice Pérol, Nick Pavlakis, Evgeny Levchenko, Marco Platania, Julio Oliveira, Silvia Novello, Rita Chiari, Teresa Moran, Emmanuel Mitry, Eveline Nüesch, Ting Liu, Bogdana Balas, Krzysztof Konopa & Solange Peters. (2019) Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer 138, pages 79-87.
Crossref
Crossref
A. Wrona. (2019) Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?. Cancer/Radiothérapie 23:5, pages 432-438.
Crossref
Crossref
William R. Grubb, Mitchell Machtay, Afshin Dowlati & Tithi Biswas. (2019) Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. Practical Radiation Oncology 9:2, pages e129-e133.
Crossref
Crossref
Nicolaus Andratschke, Johannes Kraft, Carsten Nieder, Rebecca Tay, Raffaele Califano, Riccardo Soffietti & Matthias Guckenberger. (2019) Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer 129, pages 63-71.
Crossref
Crossref
Muhammad Khan, Jie Lin, Guixiang Liao, Yunhong Tian, Yingying Liang, Rong Li, Mengzhong Liu & Yawei Yuan. (2019) ALK Inhibitors in the Treatment of ALK Positive NSCLC. Frontiers in Oncology 8.
Crossref
Crossref
Wenhui Wang, Xin Sun & Zhouguang Hui. (2019) Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer. Oncology Research and Treatment 42:11, pages 599-606.
Crossref
Crossref
Dae Ho Lee, Hiroshi Isobe, Hubert Wirtz, Sabina Bandeira Aleixo, Phillip Parente, Filippo de Marinis, Min Huang, Ashwini Arunachalam, Smita Kothari, Xiting Cao, Nello Donnini, Ann-Marie Woodgate & Javier de Castro. (2018) Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study. BMC Health Services Research 18:1.
Crossref
Crossref
A.A. Thai & B.J. Solomon. (2018) Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?. Annals of Oncology 29:11, pages 2160-2162.
Crossref
Crossref
Frank Griesinger, Julia Roeper, Christoph Pöttgen, Kay C. Willborn & Wilfried E.E. Eberhardt. (2018) Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms. Oncotarget 9:80, pages 35181-35194.
Crossref
Crossref
Negar Chooback, Shilo Lefresne, Sally C. Lau & Cheryl Ho. (2018) CNS Metastases in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: Impact on Health Resource Utilization. Journal of Oncology Practice 14:10, pages e612-e620.
Crossref
Crossref
Grainne M. O’Kane & Natasha B. Leighl. (2018) Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. CNS Drugs 32:6, pages 527-542.
Crossref
Crossref
C. Burudpakdee, W. Wong, A. Seetasith, F.A. Corvino, W. Yeh & M. Gubens. (2018) Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer 119, pages 103-111.
Crossref
Crossref
Alesha A. Thai & Benjamin J. Solomon. (2018) Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Current Opinion in Oncology 30:2, pages 84-91.
Crossref
Crossref
Xiaoyan Li, Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y. H. Lip & Steve Deitelzweig. (2018) Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLOS ONE 13:1, pages e0191722.
Crossref
Crossref
Nicolas Girard, Delphine Cozzone, Lucie de Leotoing, Charlène Tournier, Alexandre Vainchtock, Bertrand Tehard & Alexis B. Cortot. (2018) Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis. ESMO Open 3:6, pages e000414.
Crossref
Crossref
Alexander Heinzel, Dirk Müller, Sareh Said Yekta-Michael, Garry Ceccon, Karl-Josef Langen, Felix M Mottaghy, Martin Wiesmann, Martin Kocher, Elke Hattingen & Norbert Galldiks. (2017) O-(2-18F-fluoroethyl)-L-tyrosine PET for evaluation of brain metastasis recurrence after radiotherapy: an effectiveness and cost-effectiveness analysis. Neuro-Oncology 19:9, pages 1271-1278.
Crossref
Crossref
Tristan A. Barnes, Grainne M. O’Kane, Mark David Vincent & Natasha B. Leighl. (2017) Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology 7.
Crossref
Crossref
Ugonma N Chukwueke & Priscilla K Brastianos. (2017) Sequencing brain metastases and opportunities for targeted therapies. Pharmacogenomics 18:6, pages 585-594.
Crossref
Crossref
Tyler Lazaro & Priscilla K Brastianos. (2017) Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncology 6:2, pages 139-151.
Crossref
Crossref
X. Li, S. Deitelzweig, A. Keshishian, M. Hamilton, R. Horblyuk, K. Gupta, X. Luo, J. Mardekian, K. Friend, A. Nadkarni, X. Pan & G. Y. H. Lip. (2017) Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. Thrombosis and Haemostasis 117:6, pages 1072-1082.
Crossref
Crossref
Hong Tao, Yiran Cai, Liang Shi, Junfang Tang, Zhidong Liu, Zitong Wang, Lianqi Bai & Zhe Liu. (2017) Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase-positive and surgically resected lung adenocarcinoma. Thoracic Cancer 8:1, pages 8-15.
Crossref
Crossref
Zabi Wardak & Hak Choy. (2016)
Improving Treatment Options for Brain Metastases From
ALK
-Positive Non–Small-Cell Lung Cancer
. Journal of Clinical Oncology 34:34, pages 4064-4065.
Crossref
Crossref
Chad G. RusthovenRobert C. Doebele. (2016)
Management of Brain Metastases in
ALK
-Positive Non–Small-Cell Lung Cancer
. Journal of Clinical Oncology 34:24, pages 2814-2819.
Crossref
Crossref
Benjamin J. SolomonFederico CappuzzoEnriqueta FelipFiona H. BlackhallDaniel B. CostaDong-Wan KimKazuhiko NakagawaYi-Long WuTarek MekhailJolanda PaoliniJennifer TursiTiziana UsariKeith D. WilnerPaulina SelaruTony S.K. Mok. (2016)
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced
ALK
-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
. Journal of Clinical Oncology 34:24, pages 2858-2865.
Crossref
Crossref
Solange Peters, Christin Bexelius, Veronica Munk & Natasha Leighl. (2016) The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treatment Reviews 45, pages 139-162.
Crossref
Crossref
Solange Peters. (2016) Emerging Options After Progression During Crizotinib Therapy. Journal of Clinical Oncology 34:7, pages 643-645.
Crossref
Crossref